Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) - Equities researchers at HC Wainwright boosted their Q3 2025 earnings estimates for Immix Biopharma in a report released on Wednesday, June 4th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.16) per share for the quarter, up from their prior forecast of ($0.22). HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for Immix Biopharma's current full-year earnings is ($0.87) per share. HC Wainwright also issued estimates for Immix Biopharma's Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.62) EPS.
Immix Biopharma Price Performance
Shares of IMMX stock traded down $0.03 on Friday, hitting $2.34. The stock had a trading volume of 329,467 shares, compared to its average volume of 155,874. The firm has a market capitalization of $65.23 million, a P/E ratio of -2.75 and a beta of 0.31. Immix Biopharma has a 1 year low of $1.26 and a 1 year high of $3.00. The company's 50 day moving average price is $1.91 and its 200-day moving average price is $1.95.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last announced its earnings results on Monday, March 24th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.09.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Immix Biopharma stock. Jane Street Group LLC bought a new position in shares of Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 17,523 shares of the company's stock, valued at approximately $39,000. Jane Street Group LLC owned approximately 0.06% of Immix Biopharma at the end of the most recent reporting period. Institutional investors own 11.26% of the company's stock.
About Immix Biopharma
(
Get Free Report)
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Read More
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
